

Index

A

ACA. *See* Affordable Care Act
AD. *See* Alzheimer's disease
ADA. *See* Americans with Disabilities Act
Adrenal carcinoma, genetic testing, 75
Affordable Care Act (ACA), 227
ALS. *See* Amyotrophic lateral sclerosis
Alzheimer's disease (AD)
 APOE testing, 49–50
 direct-to-consumer testing, 49–50
 gene mutations, 48
 genetic counseling, 48–49, 53
 polygenic risk scores, 50
 predictive testing, 48
Americans with Disabilities Act (ADA), 228
Amyotrophic lateral sclerosis (ALS), genetic testing
 and counseling, 51
Angelman syndrome, 63
Anxiety. *See* Psychiatric genetic counseling
APOE, 49–50, 294
APP. *See* Alzheimer's disease
Arrhythmogenic right ventricular cardiomyopathy
 (ARVC), 145, 148
ARVC. *See* Arrhythmogenic right ventricular
 cardiomyopathy
Assisted reproductive technologies. *See* Gamete donation;
 Intracytoplasmic sperm injection; In vitro
 fertilization; Preimplantation genetic testing
Attention deficit-hyperactivity disorder.
 See Neurodevelopmental disorders
Autism. *See* Neurodevelopmental disorders

B

BATHE assessment, 162–164
Bipolar disorder. *See* Psychiatric genetic counseling
BRAF, 99
BRCA1, 78, 83, 97, 101–102, 106
BRCA2, 78, 83, 101–102, 106
Breast cancer, genetic testing, 77–78, 83

C

CADD Score. *See* Combined Annotation
 Dependent Depletion Score
Cancer
 cell-free DNA, 105–106
 germline variant identification through somatic
 analysis, 106–110
Cancer. *See also specific cancers*

genetic counseling
 historical perspective, 83
 overview, 73
 pretest counseling, 84–86
 recent developments, 83–84
genetic testing
 biosample selection, 86
 direct-to-consumer testing, 78
 germline testing, 87
 guidelines, 76, 78–82
 indications, 74–76
 interpretation, 87–88
 laboratory selection, 86
 polygenic risk scores, 87
 test selection, 86–87
pediatric considerations in testing and
 counseling, 88–89
risk assessment tools, 77
tumor gene sequencing
 germline implications
 allelic fraction, 102
 discordant tumor types, 103
 filtration, 101
 founder variants, 102–103
 Lynch syndrome case example, 104–105
 overview, 101
 transcript use, 101–102
 tumor heterogeneity, 102
 tumor mutational burden, 103
 variant classification, 103–104
 techniques, 100–101
Cardiovascular disease. *See also* Sudden cardiac death
 genetic counseling
 BATHE assessment, 162–164
 coping promotion, 161–162
 diagnosis assimilation, 142–143
 genetic testing
 decision-making
 literature, 158–159
 overview, 156, 158
 indications, 156–157
 interpretation, 160–161
 psychological and social issues
 implantable cardioverter defibrillator
 decision-making, 147
 outcomes, 147–148
 research findings, 143–146, 159–160
 sports restrictions, 148–149
 sudden cardiac death
 grief, 149–151

Index

- Cardiovascular disease. (*Continued*)
 risks, 146–147
 syndromes, 141–142
CDH1, 88, 109
Cell-free DNA (cfDNA)
 prenatal screening
 aneuploidy, 27–29
 monogenetic disorders, 29–30
 overview, 15
 prospects, 34–36
 recommendations, 33
 tumors, 105–106
Cerebral palsy. *See* Neurodevelopmental disorders
cfDNA. *See* Cell-free DNA
CHARGE syndrome, 170
CHIP. *See* Clonal hematopoiesis of indeterminate potential
CHMP2B, 51
Chromosomal microarray analysis (CMA), 16, 31, 61, 63, 170, 188
Clonal hematopoiesis of indeterminate potential (CHIP), 105
CMA. *See* Chromosomal microarray analysis
Combined Annotation Dependent Depletion (CADD) Score, 173
Counsyl Complete, 7
Cystic fibrosis
 carrier screening, 292–293
 genetic counseling, 187, 194
 newborn screening, 190
 prenatal diagnosis, 32
 treatment, 192
- D**
DCM. *See* Dilated cardiomyopathy
Decision-making, prenatal genetic testing
 challenges, 14–15
 educational video, 11–12
 historical perspective, 14
 nondirective counseling, 12
 patient coaching with decision aid, 20–21
 shared decision-making model
 decision aids, 17–21
 overview, 13–14
 uncertain information and informed decisions, 16
Depression. *See* Psychiatric genetic counseling
DGC. *See* Diffuse gastric cancer
Diagnostic workup
 confirmation and results disclosure, 191–192
 test selection and interpretation for pediatrics, 188–189
 uncertainty, 189
Diffuse gastric cancer (DGC), genetic testing, 75, 108–109
Dilated cardiomyopathy (DCM), 143, 145, 158
Direct-to-consumer (DTC) testing
 Alzheimer's disease, 49–50
 cancer, 78
 legal issues, 230
 minors, 221
 personalized medicine, 294
Down syndrome, preimplantation genetic testing, 202–204, 255
DTC testing. *See* Direct-to-consumer testing
Duty to warn, at-risk relatives, 231–235
- E**
Eating disorders. *See* Psychiatric genetic counseling
ECS. *See* Expanded carrier screening
EGFR, 103
Elective genetic testing
 minors
 direct-to-consumer testing, 221
 exceptions to deferment, 217–218
 exome/genome sequencing, 218–220
 prospects, 222
 rationale for discouragement, 214–215
 position statements, 213–214
 prenatal testing
 exome/genome sequencing, 220–221
 overview, 216–217
 right not to know, 215–216
 value assessment, 218
EPCAM, 98–99
ES. *See* Exome sequencing
Eugenics, 14, 250
Everolimus, 69
Exome sequencing (ES), 33, 35–36, 170, 218–221
Expanded carrier screening (ECS), 30, 293
- F**
False-negative rate, cell-free DNA screening, 28–29
False-positive rate, cell-free DNA screening, 28
Family-centered counseling, pediatric common diseases, 187–188
Fetal cell, identification in maternal blood, 36
Fetal fraction (FF), cell-free DNA screening, 28–29
FF. *See* Fetal fraction
FISH. *See* Fluorescence in situ hybridization
FLCN, 97
Fluorescence in situ hybridization (FISH), 31, 203
FMRI, 61
Fragile X syndrome, 63
Frontotemporal dementia (FTD), genetic testing and counseling, 51–52
FTD. *See* Frontotemporal dementia
- G**
Gamete donation
 donors
 screening, 208–209
 types, 209–210
 genetic issues, 210
 overview, 207–208
Gastric cancer. *See* Diffuse gastric cancer

- GBA*, 52–53
GDD. *See* Global developmental delay
Genetic counseling, definition, 238–239
Genetic Information Assistant (GIA), 7
Genetic Information Nondiscrimination Act (GINA), 226–231, 234, 246
Genetic testing, genetic counseling relationship, 5
GIA. *See* Genetic Information Assistant
GINA. *See* Genetic Information Nondiscrimination Act
Global developmental delay (GDD).
 See Neurodevelopmental disorders
- H**
- HCM. *See* Hypertrophic cardiomyopathy
HD. *See* Huntington's disease
Health Insurance Portability and Privacy Act (HIPAA), 229, 232–235
Hereditary nonpolyposis colorectal cancer syndrome.
 See Lynch syndrome
HIPAA. *See* Health Insurance Portability and Privacy Act
Humanism
 genetic counseling
 aligning with humanistic goals, 244–246
 nonhumanistic aspects, 241–243
 role, 239–241
 overview, 237–238
Huntington's disease (HD)
 gene discovery, 43–44
 genetic counseling for predictive testing
 prospects, 47–48
 protocol, 44–45
 session characteristics, 46–47
 predictive testing
 outcomes, 45–46
 protocol, 44–45
Hypertrophic cardiomyopathy (HCM), 143, 145, 148–149, 158
- I**
- ICD. *See* Implantable cardioverter defibrillator
ICSI. *See* Intracytoplasmic sperm injection
Implantable cardioverter defibrillator (ICD)
 decision-making, 147
 outcomes, 147–148
In vitro fertilization (IVF). *See also* Preimplantation
 genetic testing
 historical perspective, 199
 principles, 200–201
Informed consent
 alternative models, 281–283
 challenges in genomics era, 279–280
 genetic counseling role, 283–284
 genomic sequencing impact on models, 278–279
 historical perspective, 276–278
 incidental and secondary findings impact, 280–281
 prospects, 283–284
 secondary findings, 281
- Intellectual disability. *See* Neurodevelopmental disorders
Intracytoplasmic sperm injection (ICSI), 200
IVE. *See* In vitro fertilization
- J**
- Jar model, psychiatric disorders, 120–122
- K**
- Kabuki syndrome, 69, 170
KRAS, 99
- L**
- Laboratory genetic counselor
 conflicts of interest, 270–271
 overview, 263–264
 prospective roles
 business development, 266–267
 education of clients and staff, 267–269
 leadership and management, 267
 research, 271–272
 variant interpretation, 272–273
 roles
 case management, 265
 communication with clients, 264
 result reporting, 264–265
 test development, 265–266
 work settings, 269–270
Learning disorders. *See* Neurodevelopmental disorders
Legal issues, genetic testing, 225–235
LMNA, 156
Long QT syndrome (LQTS), 143, 146–147, 149, 160
LQTS. *See* Long QT syndrome
LRKK2, 52–53
Lynch syndrome
 clonal hematopoiesis of indeterminate potential, 105
 immunohistochemistry, 98–99
 microsatellite instability, 98
 mismatch repair screening, 99
 tumor gene sequencing
 germline implications
 allelic fraction, 102
 case example, 104–105
 discordant tumor types, 103
 filtration, 101
 founder variants, 102–103
 overview, 101
 transcript use, 101–102
 tumor heterogeneity, 102
 tumor mutational burden, 103
 variant classification, 103–104
 techniques, 100–101
- M**
- MAPT*, 51–52
Massively parallel sequencing (MPS), 35

Index

- MECP2*, 62
Million Veterans Program (MVP), 291
MLH1, 98–99, 104
Molloy v. Meier, 232
MPS. *See* Massively parallel sequencing
MSH2, 98–99, 104
MSH6, 98–99, 104
MVP. *See* Million Veterans Program
MyCode, 291–292
- N**
- NBS. *See* Newborn screening
NDD. *See* Neurodevelopmental disorders
Neurodevelopmental disorders (NDD)
 definitions, 60
 etiology, 60–61
 genetic counseling
 decision-making about testing, 65–66
 delivery of diagnosis, 67
 hope fostering, 68
 meaning-making, 68–69
 parental attitudes toward diagnosis, 63–64
 recurrence risk, 66–67
 relationship between genetics and disorders, 64–65
 social support opportunities, 69
 stigma, shame, and guilt, 69
 uncertainty management, 67–68
 genetic testing, 61–63
 treatment prospects, 69–70
Newborn screening (NBS), referrals, 189–191
Next-generation sequencing (NGS), 31–32, 62–63, 98, 100
NGS. *See* Next-generation sequencing
NOTCH1, 110
- O**
- OPDG. *See* Ottawa Personal Decision Guide
Ottawa Personal Decision Guide (OPDG), 17–19
Ovarian cancer, genetic testing, 75, 77–78, 83
- P**
- Pancreatic cancer, genetic testing, 75–77
Parkinson's disease (PD), genetic testing and
 counseling, 52–53
Pate v. Threlkel, 231–232
PD. *See* Parkinson's disease
Personalized medicine
 genetic counseling as keystone, 296–297
 overview, 289–290
 precision health, 290
 public perspective, 294–296
PGRN, 51
PGT. *See* Preimplantation genetic testing
Pheochromocytoma, genetic testing, 76
PMS2, 98–99, 104
POLD, 105–106
POLE, 105–106
- Polygenic risk score (PRS)
 Alzheimer's disease, 50
 cancer, 87
Polygenic risk score, psychiatric disorders, 132–133, 136
Population genomic sequencing, initiatives, 290–294
Practice models, genetic counseling, 3–4
Precision Medicine Initiative, 291
Preimplantation genetic testing (PGT)
 aneuploidy, 202–204
 common pediatric diseases, 193
 historical perspective, 250
 HLA matching, 206–207, 249
 mitochondrial disease, 207, 258
 monogenetic disease, 205
 nondisclosing monogenetic testing, 205–206
 principles, 201–202
 regulation
 genetic counseling regulation, 255–256, 259
 medical necessity requirement, 256–257
 permissiveness degree, 252–253
 policy approach, 251–252
 reproductive tourism, 258
 sex selection, 257–258
 trends, 254
 sex selection, 250
 structural chromosome rearrangement, 204–205
 variants of uncertain significance, 207
Prenatal genetic testing. *See also specific diseases*
 counseling session components, 26–27
 decision-making. *See* Decision-making,
 prenatal genetic testing
 diagnostic tests
 aneuploidy, 31
 microdeletions/microduplications, 31–32
 monogenetic disorders, 32
 recommendations, 32–33
 techniques, 31
 patient perspectives, 36
 prenatal treatment options, 36–37
 prospects, 34–36
 screening tests
 aneuploidy, 27
 cell-free DNA, 27–30
 microdeletions, 29
 monogenetic disorders, 29–30
 multiple marker screening, 27
 recommendations, 32
 reproductive carrier screening, 30–31
PRS. *See* Polygenic risk score
PSEN1. *See* Alzheimer's disease
PSEN2. *See* Alzheimer's disease
Psychiatric genetic counseling
 appointment and follow-up, 118
 case load, 118
 diagnosis confirmation, 117–118
 historical perspective, 116–117
 outcome evaluation, 118, 125–126
 overview, 115–116

- preappointment procedures, 117
 - process and content
 - etiology, 120–122
 - familial recurrence chances, 123–124
 - initial contracting, 120
 - overview, 118–119
 - recovery, 122–123
 - session closing, 124
 - symptom impact on session, 124–125
 - prospects, 126
 - rationale, 116
 - risk assessment
 - family history
 - data collection, 133–134
 - provision of risks, 136
 - recurrence risks, 123–124, 134–136
 - overview, 129–130
 - polygenic risk score, 132–133
 - prospects, 136–137
 - schizophrenia
 - comorbidity with other disorders, 131
 - genetics
 - copy number variants, 131
 - functional categories of genes, 131
 - rare variants, 131
 - variants with small effect sizes, 130–131
 - nongenetic risk factors, 132
 - team, 117
 - training, 118
 - PTEN*, 62
- R**
- Rare disease
 - definition, 169–170
 - diagnostic odyssey, 177–179
 - genetic counseling, 175
 - genetic testing
 - incidental and secondary findings, 175–176
 - sequencing
 - exome versus genome sequencing, 171
 - indications, 171–172
 - limitations, 171
 - neonates, 172
 - techniques, 170
 - variant classification, 172–175
 - neonatal intensive care unit genetic testing and counseling, 172, 179
 - Reciprocal engagement model (REM), tenets for genetic counseling, 2–3
 - RECQL1*, 110
 - REM. *See* Reciprocal engagement model
 - RET*, 83
 - Retinoblastoma, genetic testing, 76
 - REVEAL study, 49
- S**
- Safer v. Estate of Pack*, 231–232
 - Scalability, genetic counseling resources, 5–8
 - SCD. *See* Sudden cardiac death
 - Schizophrenia. *See* Psychiatric genetic counseling
 - SDM model. *See* Shared decision-making model
 - Service delivery models, genetic counseling, 5–7
 - Shared decision-making (SDM) model
 - decision aids, 17–21
 - overview, 13–14
 - Siblings, carrier testing, 192–193
 - SIDS. *See* Sudden infant death syndrome
 - SNCA*, 52
 - SOD1*, 51
 - Sperm donor. *See* Gamete donation
 - Sudden cardiac death (SCD)
 - grief, 149–151
 - psychological impact of young death, 144
 - risks, 146–147
 - Sudden infant death syndrome (SIDS), 143
- T**
- Tarasoff v. Regents of the University of California*, 232–233
 - TP53*, 88, 101